NCT02750501 - Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions

Cystic Fibrosis

Interventions

DEVICE

RELiZORB (immobilized lipase) cartridge

Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge

OTHER

Impact Peptide 1.5

Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding

Trial Locations (10)

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

Joe DiMaggio Children's Hospital / Memorial Healthcare System, Hollywood

Nationwide Children's Hospital, Columbus

Riley Hospital for Children at Indiana University Health, Indianapolis

Helen DeVos Children's Hospital CF Care Center, Grand Rapids

Cardinal Glennon Children's Hospital / Saint Louis University, St Louis

Children's Mercy Hospital, Kansas City

St. Luke's CF Center of Idaho, Boise

Maine Medical Center, Portland

Dayton Children's Hospital, Dayton